advertisement
Abstract #26547 Published in IGR 12-3
IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma
Hommer A; Mohammed Ramez O; Burchert M; Kimmich FCurrent Medical Research and Opinion 2010; 26: 1905-1913
Objective: Tafluprost, the first preservative-free prostaglandin analogue for topical ophthalmic use to lower IOP, was introduced in Germany in 2008. After the approval for ophthalmic use, an open-label, multicentre, observational study was conducted between October 2008 and April 2009. Major objectives of this study were to evaluate the real world efficacy, local tolerability and safety of this first in class preservative-free prostaglandin preparation in patients with ocular hypertension and glaucoma. Methods: A total of 544 patients were treated with the preservative-free formulation of tafluprost 0.0015. The majority of these patients had poor IOP control and/or poor local tolerance of their medication prior change of medication. The decision to change the previous therapy or to initiate treatment was made solely by the participating ophthalmologists. IOP readings were recorded at baseline before changing medication or initiating treatment in newly diagnosed patients, 46 weeks and 12 weeks after change of medication or initiation of treatment with preservative-free tafluprost. In addition, patient demographics, subjective symptoms (i.e. burning, foreign body sensation, itching and stinging) and objective clinical signs such as conjunctival hyperaemia were collected. Subjective symptoms were evaluated using a 4 point scale ranging from 'no symptoms', 'mild symptoms', 'moderate symptoms' to 'severe symptoms'. As a clinical sign severity of conjunctival hyperaemia was evaluated. All adverse events were collected. Results: Three hundred and sixty patients were switched from monotherapy, 45 patients were nave to treatment. A total of 139 patients were treated with fixed or non-fixed combinations prior to changing medication. In these patients preservative-free tafluprost was used either as a substitution for the fixed or non-fixed combination, as an add-on to the existing combination therapy or as one agent in a newly initiated treatment regimen. Preservative-free tafluprost provided an IOP decrease in most pre-treatment subgroups, with an overall reduction of IOP in all patients (N544) from 19.4(plus or minus)5.0mmHg at baseline to 15.7(plus or minus)4.1mmHg after 4 to 6 weeks and to 15.3(plus or minus)3.5mmHg after 12 weeks. Both values were significantly lower than treated baseline IOP (p<0.001). An IOP of 18mmHg was achieved in 79.5 of eyes treated with the preservative-free formulation of tafluprost 12 weeks after changing medication. Both subjective symptoms and objective clinical signs improved after changing medication. Only a few adverse events occurred during the follow-up period. Conclusions: Although this study was limited by its observational design, the results demonstrate that preservative-free tafluprost is an effective, well tolerated, and safe medication in a patient population with poor IOP control and/or tolerability issues with their medication prior used.
F. Kimmich. Woeschbacherstr. 37, D-76327 Pfinztal, Germany. F.Kimmich@eyecons.de
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
